{"paper_id":"f02216d4-2b91-466d-bbed-683b8500707c","body_text":"Abstract\nPurpose\nOur aim was to study the role of AK000953 silencing for the killing effect of danazol on uterine fibroids.\nMethods\nQuantitative PCR was applied to identify differential expression of AK000953 in uterine fibroid tissue and normal uterine tissue. Then we isolated and cultured uterine fibroid cells, designed the siRNA of AK000953 to silence its expression in uterine fibroid cells, and detected the treatment effect of danazol and AK000953 siRNA on cell proliferation, cell apoptosis, and cell invasion. Finally, guinea pig model of uterine fibroids was constructed to verify the effect of AK000953 silencing on uterine fibroid treatment with danazol in vivo.\nResults\nQuantitative PCR showed that the AK000953 gene was highly expressed in uterine fibroid tissue compared with normal uterine tissue (2.1 ± 0.15 vs. 0.8 ± 0.05, p < 0.01). After AK000953 silencing in uterine fibroid cells, we discovered that the inhibition rate in danazol-siRNA group was 56 ± 5 %, the cell apoptosis rate of danazol-siRNA group was 43 ± 2.3 %, and the invasion rate of uterine fibroid cells was 12 ± 1 %, which all showed significant differences with the control group or danazol group. Guinea pig model confirmed that the treatment of danazol and AK000953 siRNA effectively inhibited the development of fibroids in vivo.\nConclusion\nAK000953 silencing could effectively enhance the killing effect of danazol on uterine fibroid cells.\nSimilar content being viewed by others\nReferences\nStewart EA (2001) Uterine fibroids. Lancet 357(9252):293–298\nRabinovici J, David M, Fukunishi H, Morita Y, Gostout BS, Stewart EA (2010) Pregnancy outcome after magnetic resonance–guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril 93(1):199–209\nLethaby A, Vollenhoven B, Sowter M (2011) Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids (review)\nPron G, Bennett J, Common A, Wall J, Asch M, Sniderman K (2003) The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril 79(1):120–127\nEdwards RD, Moss JG, Lumsden MA, Wu O, Murray LS, Twaddle S, Murray GD (2007) Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med 356(4):360–370\nSankaran S, Manyonda IT (2008) Medical management of fibroids. Best Pract Res Clin Obstet Gynaecol 22(4):655–676\nDe Leo V, Morgante G, La Marca A, Musacchio MC, Sorace M, Cavicchioli C, Petraglia F (2002) A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Saf 25(11):759–779\nKatula KS, Heinloth AN, Paules RS (2007) Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem 18(8):541–552\nTan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, Wallis DD, Milewicz DM, Reveille JD, Mayes MD (2005) Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 52(3):865–876\nZhong H, Simons JW (1999) Direct comparison of GAPDH, β-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun 259(3):523–526\nPorter KB, Tsibris J, Nicosia SV, Murphy JM, O’Brien WF, Rao PS, Spellacy WN (1995) Estrogen-induced guinea pig model for uterine leiomyomas: do the ovaries protect? Biol Reprod 52(4):824–832\nLanden CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65(15):6910–6918\nNieman LK, Blocker W, Nansel T, Mahoney S, Reynolds J, Blithe D, Wesley R, Armstrong A (2011) Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 95(2):767–772.e762\nLu D, Song H, Shi G (2013) Anti-TNF-α treatment for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 3:CD008088\nCui J, Shi Y, Zhou H, Li J (2004) The changes of gene expression profiles in hydatidiform mole and choriocarcinoma with hyperplasia of trophoblasts. Int J Gynecol Cancer 14(5):984–997\nVelazquez I, Alter BP (2004) Androgens and liver tumors: Fanconi’s anemia and non-Fanconi’s conditions. Am J Hematol 77(3):257–267\nBarbieri RL, Ryan KJ (1981) Danazol: endocrine pharmacology and therapeutic applications. Am J Obstet Gynecol 141(4):453–463\nMaruo T, Matsuo H, Shimomura Y, Kurachi O, Gao Z, Nakago S, Yamada T, Chen W, Wang J (2003) Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids 68(10):817–824\nZhao Y, Wen Y, Polan ML, Qiao J, Chen BH (2007) Increased expression of latent TGF-ß binding protein-1 and fibrillin-1 in human uterine leiomyomata. Mol Hum Reprod 13(5):343–349\nDowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26(7):1059–1065\nAcknowledgments\nThis study was supported by grants from the National Natural Science Foundation of China (No. 81302243), Lanzhou military region subject (No. CLZ13JB21, CLZ14JA11), Shannxi National Science Foundation (No. 2014JM4157).\nConflict of interest\nThe Authors declare that they have no conflicts of interest to disclose.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nAdditional information\nS. Li and L. Niu contributed equally to this work and are co-first authors.\nRights and permissions\nAbout this article\nCite this article\nLi, S., Zhang, Y., Niu, L. et al. AK000953 silencing can enhance the killing effect of danazol on uterine fibroids. Arch Gynecol Obstet 292, 1075–1081 (2015). https://doi.org/10.1007/s00404-015-3695-0\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-015-3695-0","source_license":"CC0","license_restricted":false}